TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Determinants of Lower Limb Muscle Atrophy Induced During an Hospitalization for Exacerbation of COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients aged 40 to 85 years~* COPD patients : FEV1/FVC \< 70% pred~* Hospitalization for COPD exacerbation : increased respiratory symptoms over two consecutive days with at least one major symptom (dyspnea, increased sputum volume or purity) associated with another major symptom or minor symptom (sibilant, cold, sore throat or cough)~Exclusion criteria:~* Concomitant cardiac event~* Tracheal intubation~* Chronic respiratory disease other than COPD~* Disease of locomotor apparatus, neurological or psychiatrics comorbidities

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Patients (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: NEC Screening Abdominal Radiograph vs Bowel Ultrasound in Preemies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Neonates born prior to or at 28 weeks gestation admitted to NICU at CMH~Exclusion Criteria:~* Infants with chromosomal or multiple congenital anomalies~* Unable to ultrasound the bowel (e.g. gut in silo, omphalocele, gastroschisis)~* Infants who are greater than 36 corrected weeks upon admission

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Weeks
- Healthy Volunteers: f

Study Arms:
- Arm A: AXR Only (Type: NO_INTERVENTION): Infants randomized to Arm A will obtain an abdominal x-ray (AXR) as per standard of care
- Arm B: AXR + Bowel US (Type: ACTIVE_COMPARATOR): Infants randomized to Arm B will obtain an abdominal x-ray (AXR) as per standard of care and a bowel ultrasound (BUS) as the intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Blood Flow Restriction (BFR) on Exercise and Hemodynamic Responses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults~Exclusion Criteria:~* Pregnancy~* A recent illness, recent surgery, or any medical intervention~* history of diabetes, heart disease, or other cardiovascular problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Exercise with Hokanson cuffs (Type: EXPERIMENTAL): Participants will walk on the treadmill with Hokanson cuffs inflated.
- Exercise with BStrong Bands (Type: EXPERIMENTAL): Participants will walk on the treadmill with BStrong bands inflated.
- Exercise without inflated bands/cuffs (Type: SHAM_COMPARATOR): Participants will walk on the treadmill with non-inflated BStrong bands.
- Yoga poses with BStrong bands inflated (Type: EXPERIMENTAL): Participants will perform 15-20 yoga poses with BStrong bands inflated.
- Yoga poses with BStrong bands uninflated (Type: SHAM_COMPARATOR): Participants will perform 15-20 yoga poses with uninflated BStrong bands.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Pain Neuroscience Education in At-risk Patients Following Surgery for Lumbar Radiculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for surgery for lumbar radiculopathy~* Aged 18 years or older~* Willing to comply with pre-determined follow-up~* Speaking and reading Dutch fluently~* No new treatments/medication 3 weeks prior to participation and during the trial~* Having chronic back and/or leg pain ≥ 6 months~* Scoring ≥ 37/68 on the Tampa Scale for Kinesiophobia~* Scoring ≥ 30/52 on the Pain Catastrophizing Scale~Exclusion Criteria:~* Surgery for another condition~* Symptoms of cord compression or bilateral leg pain~* Other chronic illness characterized by chronic pain~* Other chronic rheumatoid, neurological, endocrinological, psychiatric or cognitive disorders~* Indicated cognitive impairment (Scoring ≤11/15 on the 5-min Telephone Montreal Cognitive Assessment)~* Pregnant or have given birth during the past year~* No access to computer, or mobile device at home~* Complications during the surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perioperative Pain Neuroscience Education (Type: EXPERIMENTAL): Patients in the experimental treatment group will receive Perioperative Pain Neuroscience Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
- Perioperative Biomedical Education (Type: ACTIVE_COMPARATOR): Patients in the control treatment group will receive Perioperative Biomedical Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Control of Epistaxis With Surgiflo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with epistaxis in emergency room.~* Epistaxis does not stop with anterior nasal packing.~Exclusion Criteria:~* Pregnancy~* Allergy or intolerance to any component of Surgiflo.~* Septal perforation.~* Nasal surgery within 3 months previous to epistaxis.~* Patients admitted to hospital for other reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasal catheter (Type: ACTIVE_COMPARATOR): In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
- Surgiflo (Type: EXPERIMENTAL): In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: IBCSG Trial 22-00 Serum Substudy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be randomized to the core protocol. Written informed consent for the serum substudy must be signed and dated by the patient and investigator~* Patient must not have begun CM maintenance (if randomized to CM maintenance)~Exclusion Criteria:~* Patient not randomized to the core protocol~* Patient already begun CM maintenance (if randomized to CM maintenance)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction chemotherapy (Type: ACTIVE_COMPARATOR): Approved induction CT regimen after randomization
- Induction chemotherapy followed by CM maintenance (Type: EXPERIMENTAL): Approved induction chemotherapy followed by 12 months of CM maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Pooling Expressed Breast Milk: A Method for Improving the Nutritional Intake of Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mother of newborn hospitalized in intensive care unit~* Mother using a breast pump in the unit and / or at home~* Mother respected the rules of handling and transport breastmilk~* No opposition mother~Exclusion Criteria:~* refusal

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive and Hormonal Treatment of Sex Offenders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Men sentenced for paraphilia~Exclusion Criteria:~Men above 70 years and men that does not speak english

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- cognitive and hormone treatment (Type: EXPERIMENTAL): cognitive and hormone (Leuprorelin) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Restoration of Atrioventricular Synchrony Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet current indications for an implantable cardioverter-defibrillator (ICD) implant with:~* QRS width \< 120 msec~* Left ventricular ejection fraction (LVEF) \< 35% (no more than 180 days prior to enrollment)~* NYHA functional class II/III~* Optimal pharmacological heart failure therapy~* PR interval \>/= 230 msec~* Ability to tolerate protocol required programming~* Access to a telephone line compatible with the LATITUDE® Communicator~* Subjects in sinus rhythm at the time of the baseline visit and who are expected to remain in sinus rhythm for the duration of the study~* Age 18 or above, or of legal age to give informed consent specific to state and national law~* Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigational center and return to the investigational center at the intervals defined by this protocol~Exclusion Criteria:~* Previously placed pacemaker, ICD, or CRT device~* Inability or refusal to sign the Informed Consent Form~* Documented life expectancy of less than 12 months or expected to undergo heart transplant within the next 12 months~* Have tricuspid valve disease or who are likely to receive a mechanical tricuspid valve during the course of the clinical investigation~* Inability or refusal to comply with the follow-up schedule~* Have a neuromuscular, orthopedic, or other noncardiac condition that prevents subject from normal unsupported walking for the six minute hall walk test~* Have surgically uncorrected primary valvular heart disease~* Second or third degree atrioventricular block (AVB)~* Permanent or persistent atrial tachyarrhythmia that is refractory to all therapies~* Have had cardiac surgery, percutaneous coronary intervention, or myocardial infarction within 3 months of signing consent or who are likely to undergo a cardiac surgery or procedure in the foreseeable future~* Enrolled in any concurrent study unless written approval has been obtained from Boston Scientific or The Integra Group~* Women who are pregnant or plan to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device programming modifies AV timing (Type: EXPERIMENTAL): DDD-40-BiV
- Device programming allows intrinsic AV timing. (Type: NO_INTERVENTION): VVI-40-RV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Analysis of the Predictive Potential of Pre-operative

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To prevent post-operative atrial fibrillation~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male of female of at least 19 years old~* Patients diagnosed with acute or chronic gastritis by gastroscopy~* Patients with one or more erosions found by gastroscopy~Exclusion Criteria:~* Patients with peptic ulcer and gastroesophageal reflux disease~* Patients with previous gastrointestinal surgery~* Patients with history of gastrointestinal cancer

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DWC20155/DWC20156 Combination Therapy (Type: EXPERIMENTAL): None
- DWC20155 Monotherapy (Type: ACTIVE_COMPARATOR): None
- DWC20156 Monotherapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women, 16 to 49 years of age~* Diagnosed with endometriosis by means of documented surgical visualization (laparoscopy or laparotomy) within 10 years of study entry~* No endometriosis-related surgical procedures within a month of starting study agent~* Has at least 2 days of moderate or severe pain scores for dysmenorrhea (E-diary NRS \> 5 of 10) and non-menstrual pelvic pain (E-diary NRS \> 5 of 10) during the month prior to starting study agent~* Must have had a menstrual cycle of interval 24-35 days within 3 months of starting study agent~* BMI 18 to 39~* Able to provide written informed consent and able to comply with study procedures for the entire length of the study~Exclusion Criteria:~* Pregnant or breastfeeding or planning pregnancy in the next 12 months~* Has been pregnant within 3 months of starting study agent~* Has had a hysterectomy or bilateral oophorectomy~* Has chronic pelvic pain not caused by endometriosis (i.e. inflammatory bowl disease, irritable bowel syndrome, adenomyosis, interstitial cystitis, pelvic adhesive disease, pelvic inflammatory disease) that requires chronic analgesic or narcotic use which would interfere with assessment of endometriosis associated pain~* Current history of undiagnosed abnormal uterine bleeding~* Currently receiving Gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist or have received any of these types of medications within 6 months of starting study agent~* Currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or i.m. medroxyprogesterone acetate (DMPA-IM) or have received any of these within the last 3 months of enrollment~* Currently has an intrauterine device in place~* Use of steroids or immunosuppressive medications on a regular basis within 3 months of enrollment~* Has an unstable medical condition, chronic disease or psychiatric disorder that is deemed by the investigator to be incompatible with participation in the study~* Treatment with any other investigational drug/interventions within 3 months of starting study agent~* History of drug or alcohol abuse

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Electro-kinetically Modified Water (Type: EXPERIMENTAL): Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multi trauma patients~* Femur or pelvic fracture~* Injury Severity Score (ISS) ≥ 18~* Age 18-80 yrs~Exclusion Criteria:~* Congenital C1-inhibitor deficiency~* Use of immune suppressants~* Pregnancy~* Known hypersensitivity for blood products~* Fixation of femur fracture with external fixation or osteosynthesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- C1-esterase inhibitor (Type: ACTIVE_COMPARATOR): C1-esterase inhibitor, 100 U/kg bodyweight
- Saline 0.9% (Type: PLACEBO_COMPARATOR): Saline 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with cancer metastatic to either the liver or lungs~* Subjects Scheduled for regular CT surveillance examinations~* Subjects with life expectancy of at least 6 months~Exclusion Criteria:~* Age \<18 years~* No written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Helmet Continuous Positive Airway Pressure Versus Oxygen Venturi in Acute Respiratory Failure in CAP: CAPOVeRSO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-acquired pneumonia (CAP) defined as: new chest x-ray pulmonary infiltrate, fever, and respiratory symptoms~* Acute Hypoxemic Respiratory failure~* Respiratory Rate \< 35 breaths/min~* PaO2/FiO2 \> 200 and \< 300 while breathing oxygen for at least 15 minutes via a Venturi mask with FiO2 0.5~Exclusion criteria~* Immunosuppression~* acute cardiogenic pulmonary edema~* Patients belonging to Class II-III-IV of the NYHA~* Acute coronary syndrome~* Acute Respiratory Acidosis pH \< 7.35 and PaCO2 \> 45 mmHg~* More than 3 acute organ failures~* Systolic Pressure \< 90 mmHg under fluid resuscitation or vasopressor drug use~* Seizures~* Decreased level of consciousness (GCS \<12)~* Inability to clear secretions~* Pre-defined intubation criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): CPAP delivered by a helmet
- 2 (Type: NO_INTERVENTION): O2 administration via a conventional Venturi mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy